Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 11

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 11
---
 existing cardiovascular conditions. No assurances can be made that we will successfully integrate Antev into our business and operations or successfully develop Teverelix.

See "Risk Factors-We may not successfully integrate Antev into our business and operations or successfully develop Teverelix."

Warrant Inducement Agreement

On July 14, 2025, we entered into a warrant inducement agreement with Armistice Capital Master Fund Ltd. ("Armistice") (the "Warrant Inducement Agreement"), pursuant to which Armistice agreed to exercise existing warrants to purchase up to 1,340,000 of the Company's common shares issued on March 10, 2025 with an exercise price of $2.80 per Common Share (the "Regulation A Warrants"), in consideration for receiving the 2,680,000 warrants to purchase common shares with an exercise price of $3.75 (the "Private Warrants"). In accordance with the Warrant Inducement Agreement, Armistice exercised its Regulation A Warrants for cash, for gross proceeds of $3,752,000 to the Company.

<div align='center'>4</div>

Other Corporate Updates

On May 22, 2025, the Company announced that it has received study may proceed approval from the United Arab Emirates Department of Health to commence Phase 2 clinical study (SKNJCT-004) to non-invasively treat basal cell carcinoma ("BCC") of the skin.

On June 23, 2025, the Company announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO"). Mr. Smith first joined the Company as a consultant on May 27, 2025 and transitioned to his new role as COO on June 30, 2025.

On July 29, 2025, the Company and Deloitte LLP ("Deloitte") entered into an engagement letter whereby Deloitte was appointed as the exclusive lead financial adviser to the Company for the purpose of finding one or more partners for an out-licensing transaction for D-MNA for the treatment of BCC in adults, whether by license, option, or other agreed structure or mechanism.

On August 4, 2025, the Company announced that it entered into a non-binding memorandum of understanding with Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune system